"Sitagliptin Phosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.
| Descriptor ID |
D000068900
|
| MeSH Number(s) |
D03.383.129.799.725 D03.383.679.875
|
| Concept/Terms |
Sitagliptin Phosphate- Sitagliptin Phosphate
- Phosphate, Sitagliptin
- Sitagliptin Phosphate Monohydrate
- Monohydrate, Sitagliptin Phosphate
- Phosphate Monohydrate, Sitagliptin
- Sitagliptin Monophosphate Monohydrate
- Monohydrate, Sitagliptin Monophosphate
- Monophosphate Monohydrate, Sitagliptin
MK 0431- MK 0431
- 0431, MK
- MK0431
- MK-0431
Sitagliptin- Sitagliptin
- 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
|
Below are MeSH descriptors whose meaning is more general than "Sitagliptin Phosphate".
Below are MeSH descriptors whose meaning is more specific than "Sitagliptin Phosphate".
This graph shows the total number of publications written about "Sitagliptin Phosphate" by people in this website by year, and whether "Sitagliptin Phosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sitagliptin Phosphate" by people in Profiles.
-
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
-
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
-
Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
-
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.